Secukinumab, an interleukin–17A antibody, has been approved for treatment of psoriasis and PsA in the United States. PubMed, Curr Opin Rheumatol, 2016 May;28(3):204-10. (Also see Psoriasis and Psoriatic Arthritis)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.